US009511067B2

(12) **United States Patent**
Hadida Ruah et al.

(10) **Patent No.: US 9,511,067 B2**
(45) **Date of Patent: *Dec. 6, 2016**

(54) **SUBSTITUTED SPIRO[PIPERIDINE-4,1'-PYRROLO[1,2-A]PYRAZINE]S AS MODULATORS OF ION CHANNELS**

(71) Applicant: **Vertex Pharmaceuticals Incorporated**, Boston, MA (US)

(72) Inventors: **Sara Sabina Hadida Ruah**, La Jolla, CA (US); **Edward Adam Kallel**, Escondido, CA (US); **Mark Thomas Miller**, San Diego, CA (US); **Vijayalaksmi Arumugam**, San Marcos, CA (US); **Jason McCartney**, Cardiff by the Sea, CA (US); **Corey Anderson**, San Diego, CA (US); **Peter Diederik Jan Grootenhuis**, San Diego, CA (US); **Licong Jiang**, San Diego, CA (US)

(73) Assignee: **VERTEX PHARMACEUTICALS INCORPORATED**, Boston, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/578,628**

(22) Filed: **Dec. 22, 2014**

(65) **Prior Publication Data**

US 2015/0174127 A1 Jun. 25, 2015

Related U.S. Application Data

(62) Division of application No. 13/364,586, filed on Feb. 2, 2012, now Pat. No. 8,916,565.

(60) Provisional application No. 61/438,685, filed on Feb. 2, 2011, provisional application No. 61/440,987, filed on Feb. 9, 2011, provisional application No. 61/495,538, filed on Jun. 10, 2011.

(51) **Int. Cl.**

A61K 31/4985	(2006.01)
C07D 471/20	(2006.01)
A61K 31/499	(2006.01)
C07D 519/00	(2006.01)
A61K 31/506	(2006.01)

(52) **U.S. Cl.**
CPC ***A61K 31/499*** (2013.01); ***A61K 31/506*** (2013.01); ***C07D 471/20*** (2013.01); ***C07D 519/00*** (2013.01)

(58) **Field of Classification Search**
CPC A61K 31/4985; C07D 471/20
USPC 514/250; 544/336
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,939,159	A	2/1976	Dornauer et al.
4,353,901	A	10/1982	Clark
5,206,240	A	4/1993	Baldwin et al.
5,633,247	A	5/1997	Baldwin et al.
7,674,803	B2	3/2010	Guedat et al.
2002/0013325	A1	1/2002	Fisher et al.
2002/0082264	A1	6/2002	Nikolic et al.
2002/0151712	A1	10/2002	Lin et al.
2004/0014744	A1	1/2004	Haviv et al.
2004/0266802	A1	12/2004	Calvet et al.
2005/0209262	A1	9/2005	Tomori et al.
2006/0052597	A1	3/2006	Best et al.
2007/0066584	A1	3/2007	Yao et al.
2007/0078120	A1	4/2007	Ban et al.
2007/0117824	A1	5/2007	Berk et al.
2008/0255154	A1	10/2008	Yao et al.
2009/0169567	A1	7/2009	Kokubo et al.
2009/0186901	A1	7/2009	Reiser et al.
2009/0192182	A1	7/2009	Kusumi et al.
2009/0215742	A1	8/2009	Funk et al.
2009/0325992	A1	12/2009	Hanada et al.
2010/0113418	A1	5/2010	Fukatsu et al.
2011/0306607	A1	12/2011	Hadida-Ruah et al.
2012/0245136	A1	9/2012	Hadida-Ruah et al.
2012/0264749	A1	10/2012	Hadida-Ruah et al.

FOREIGN PATENT DOCUMENTS

CA	2489255	12/2003
EP	0 002 937	7/1979
EP	0 370 732	5/1990
EP	0 431 943	6/1991
EP	2 123 652	11/2009
GB	1 590 155	5/1981
JP	4 297458	10/1992
WO	WO 92/15304	9/1992
WO	WO 95/15327	6/1995
WO	WO 95/30642	11/1995
WO	WO 97/02248	1/1997
WO	WO 97/11940	4/1997
WO	WO 97/16729	5/1997
WO	WO 02/20509	3/2002
WO	WO 03/095427	11/2003
WO	WO 03/104240	12/2003
WO	WO 2004/037800	5/2004

(Continued)

OTHER PUBLICATIONS

Office Action dated Mar. 4, 2015 in U.S. Appl. No. 13/398,184, filed Feb. 16, 2012.

Office Action dated Oct. 1, 2014, in U.S. Appl. No. 13/398,184, filed Feb. 16, 2012.

Artico, M., et al. "One-Pot Synthesis of Novel Spiro-Annelated Pyrrole-Containing Heterocyclic Systems from Suitable Synthons", J. Heterocyclic Chem., 1992, p. 241-245, vol. 29.

Fletcher, Stephen, et al., "4-(Phenylsulfonyl)piperidines: Novel, Selective, and Bioavailable 5-HT_{2A} Receptor Antagonists", J. Med. Chem, 2002, p. 492-503, vol. 45.

Hackam, Daniel G. et al. "Translation of Research Evidence From Animals to Humans", JAMA, 2006, p. 1731-1732, vol. 14.

Jordan, V. Craig, "Tamoxifen: A most unlikely pioneering medicine", Nature Review—Drug Discovery, 2003, p. 205-213, vol. 2.

(Continued)

Primary Examiner — Douglas M Willis
(74) *Attorney, Agent, or Firm* — Brinks Gilson & Lione

(57) **ABSTRACT**

The invention relates to pyrrolopyrazine-spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

30 Claims, No Drawings